DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» BIIB033
BIIB033
Ectrims Meeting November 2015
Monoclonal Antibodies As Neurological Therapeutics
Q3 Tnt Submission Revised Sheet.Xlsx
WO 2016/025911 Al 18 February 2016 (18.02.2016)
Company Data, Credit Suisse Analysis Slide 4 September 2013 Our Top-10 Sound Bites/Observation/Questions/Focal Points for the Conference(Cont.)
The Future of MS Treatments
09/H0402/92 20080763 Panitumumab Vs C
MS ECHO: Highlights from the Consortium of Multiple Sclerosis Centers 2015 Annual Meeting
WO 2014/144600 A2 18 September 2014 (18.09.2014) P O P CT
PDF of Antibody News
ERANSKINA ANEXO I+G Proiektuen, Azterlan Klinikoen Eta Argitalpen Zientifikoen Zerrenda Proyectos De I+D, Estudios Clínicos Y Lista De Publicaciones Científicas 1
1 Freedman Review of Available Therapies
2017 MS Research Update Is Made Possible Through Contributions in Honor Of: Dr
University Hospitals of Leicester NHS Trust Research & Development Directorate Performance in Delivering Research
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
( 12 ) United States Patent
Anti-LINGO-1 Has No Detectable Immunomodulatory Effects in Preclinical and Phase 1 Studies
Multiple Sclerosis: Focus on Daclizumab
Top View
Highlights from the AAN 2015 Annual Meeting
MS Academia: Multiple Sclerosis Advanced Course
B Cell Targeted Therapy in Multiple Sclerosis – New Possibilities
Eranskina Anexo
Next Generation Antibody Drugs: Pursuit of the 'High-Hanging Fruit'
Monoclonal Antibodies for Multiple Sclerosis Treatment, Sclerosis for Multiple Antibodies Monoclonal F
(19) United States Mar. 12, 2015
The Evolving Landscape of MS Treatment
Multiple Sclerosis
CAPTURE Study 2089
Neurology Clinical Trials 2018
A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future